1. Home
  2. SPRO vs ZCMD Comparison

SPRO vs ZCMD Comparison

Compare SPRO & ZCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • ZCMD
  • Stock Information
  • Founded
  • SPRO 2013
  • ZCMD 2012
  • Country
  • SPRO United States
  • ZCMD China
  • Employees
  • SPRO N/A
  • ZCMD N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • ZCMD Other Consumer Services
  • Sector
  • SPRO Health Care
  • ZCMD Real Estate
  • Exchange
  • SPRO Nasdaq
  • ZCMD Nasdaq
  • Market Cap
  • SPRO 33.0M
  • ZCMD 29.0M
  • IPO Year
  • SPRO 2017
  • ZCMD 2020
  • Fundamental
  • Price
  • SPRO $3.02
  • ZCMD $1.49
  • Analyst Decision
  • SPRO Buy
  • ZCMD
  • Analyst Count
  • SPRO 4
  • ZCMD 0
  • Target Price
  • SPRO $5.00
  • ZCMD N/A
  • AVG Volume (30 Days)
  • SPRO 12.5M
  • ZCMD 502.4K
  • Earning Date
  • SPRO 08-04-2025
  • ZCMD 01-01-0001
  • Dividend Yield
  • SPRO N/A
  • ZCMD N/A
  • EPS Growth
  • SPRO N/A
  • ZCMD N/A
  • EPS
  • SPRO N/A
  • ZCMD N/A
  • Revenue
  • SPRO $44,584,000.00
  • ZCMD $15,864,773.00
  • Revenue This Year
  • SPRO N/A
  • ZCMD N/A
  • Revenue Next Year
  • SPRO N/A
  • ZCMD N/A
  • P/E Ratio
  • SPRO N/A
  • ZCMD N/A
  • Revenue Growth
  • SPRO N/A
  • ZCMD N/A
  • 52 Week Low
  • SPRO $0.51
  • ZCMD $0.95
  • 52 Week High
  • SPRO $3.06
  • ZCMD $2.97
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 79.94
  • ZCMD 57.05
  • Support Level
  • SPRO $2.81
  • ZCMD $1.04
  • Resistance Level
  • SPRO $3.06
  • ZCMD $1.41
  • Average True Range (ATR)
  • SPRO 0.24
  • ZCMD 0.14
  • MACD
  • SPRO -0.00
  • ZCMD 0.02
  • Stochastic Oscillator
  • SPRO 93.75
  • ZCMD 89.85

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

Share on Social Networks: